| 向奎 崔应东 李时军 崔雁飞 占立君 陈强胜.琥珀酸索利那新对女性膀胱活跃症患者P2X3受体表达的影响[J].现代生物医学进展英文版,2015,15(29):5698-5701. |
| 琥珀酸索利那新对女性膀胱活跃症患者P2X3受体表达的影响 |
| Effect of Solifenacin on P2X3 Receptor Expression in Female Patients withBladder Active Disease |
| |
| DOI： |
| 中文关键词: 琥珀酸索利那新 膀胱活跃症 P2X3 受体 |
| 英文关键词: Solifenacin Bladder active disease P2X3 receptor |
| 基金项目:湖北省自然科学基金项目(2008CDB145) |
|
| Hits: 757 |
| Download times: 0 |
| 中文摘要: |
| 目的：探讨琥珀酸索利那新对女性膀胱活跃症患者的治疗效果及对膀胱内P2X3 受体的表达的影响。方法：选取我院收治的
女性膀胱活跃症患者76 例，随机分为两组，对照组38 例，予托特罗定2 mg，早晚日2 次口服；实验组38 例，予琥珀酸索利那新5
mg，日1次口服，2 周为1 个疗程，治疗2 个疗程。比较两组患者的24 h排尿次数和尿急次数情况，初始尿意容量、最大尿流率、最
大膀胱压容量的变化，以及膀胱内P2X3 受体的表达情况。结果：治疗前两组患者尿急次数、排尿次数、尿意容量、最大尿流率及最
大膀胱压容量无统计学差异，P＞0.05；治疗后，患者尿急次数及排尿次数降低，尿意容量、最大尿流率、最大膀胱压容量升高，与对
照组比较，实验组改善更明显，差异具有统计学意义，P＜0.05。P2X3 受体主要表达于膀胱黏膜层和黏膜下层，染色为棕黄色或金
黄色；实验组P2X3 表达低于正常组，差异具有统计学意义，P＜0.05。结论：琥珀酸索利那新能够缓解女性膀胱活跃症患者临床症
状，其治疗机制可能为抑制了P2X3 受体的表达。 |
| 英文摘要: |
| Objective:To investigate the effect of solifenacin on P2X3 receptor expression in female patients with bladder active
disease.Methods:76 cases of female bladder active patients were randomly divided into two groups. 38 cases treated with Todd Luoding
2 mg twice a day. The experimental group of 38 cases was treated with solifenacin 5 mg, once a day, 2 weeks for 1 course, totally 2
courses. The change of 24 h micturition frequency and urgency number, meaning initial urine volume, maximum urine flow rate, maximumbladder
pressure capacity, and the expression of P2X3 receptor in bladder were detected and compared between two groups.Results:The number of urgency, urination, urine volume, urinary flow rate and maximum bladder pressure capacity of two groups of patients before
treatment had no significant difference, P > 0.05. After treatment, the number of urgency and the frequency of urination was reduced,
and the urine volume, maximum urine flow rate, maximum bladder pressure capacity was increased in two groups, but more obviously
improvement in experimental group than the control group, P＜0.05. The P2X3 receptor was mainly expressed in bladder mucosa and
submucosa, dyed brown or golden yellow. The expression of P2X3 receptor in experimental group was significantly lower than that in
control group, P< 0.05.Conclusion:Solifenacin can alleviate the clinical symptoms of patients with female bladder active patients, the
possible treatment mechanismmight be the inhibition of P2X3 receptor expression. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
